Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
$1.99
+0.3%
$1.99
$0.55
$2.01
N/AN/AN/A2,000 shs
Q BioMed Inc. stock logo
QBIO
Q BioMed
$0.00
$0.00
$0.03
$9K2.2242,087 shs4,000 shs
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
$0.00
$2.91
$82.80
$1.90M2.031,362 shs6,500 shs
VGLS
VG Life Sciences
$0.00
$0.00
$0.00
$0.00
$2.11M1.758.51 million shs300,000 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Q BioMed Inc. stock logo
QBIO
Q BioMed
0.00%0.00%0.00%0.00%0.00%
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
0.00%0.00%0.00%0.00%0.00%
VGLS
VG Life Sciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
N/AN/AN/AN/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/AN/AN/AN/AN/AN/AN/AN/A
VGLS
VG Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
0.00
N/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
0.00
N/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
0.00
N/AN/AN/A
VGLS
VG Life Sciences
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
$4.41MN/AN/AN/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
$280K0.00N/AN/AN/ANaN
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
$610K0.00N/A0.08$341.84 per share0.00
VGLS
VG Life Sciences
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
-$770KN/A0.00N/AN/AN/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
-$2.05MN/A0.00N/AN/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
-$81.15MN/A0.00N/AN/A-668.58%-163.22%-52.10%N/A
VGLS
VG Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
N/AN/AN/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
N/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/AN/AN/AN/AN/A
VGLS
VG Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
N/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
N/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
0.05
1.17
1.07
VGLS
VG Life Sciences
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
N/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
N/A
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/A
VGLS
VG Life Sciences
N/A

Insider Ownership

CompanyInsider Ownership
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
12.90%
Q BioMed Inc. stock logo
QBIO
Q BioMed
28.20%
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
N/A
VGLS
VG Life Sciences
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Polydex Pharmaceuticals Limited stock logo
POLXF
Polydex Pharmaceuticals
20N/AN/ANot Optionable
Q BioMed Inc. stock logo
QBIO
Q BioMed
391.97 million104.18 millionNot Optionable
ReShape Lifesciences Inc. stock logo
RSLSD
ReShape Lifesciences
50354,000N/ANot Optionable
VGLS
VG Life Sciences
121.10 billionN/ANot Optionable

Recent News About These Companies

VG Life Sciences Inc.
VG Life Sciences Inc. (VGLS)
VG Life Sciences Inc VGLS
Report warns of 'oversupply' of life sciences real estate
VGLS VG Life Sciences Inc.

Media Sentiment Over Time

Polydex Pharmaceuticals stock logo

Polydex Pharmaceuticals OTCMKTS:POLXF

$1.99 +0.01 (+0.30%)
As of 08/7/2023

Polydex Pharmaceuticals Ltd. is a development stage company, which engages in manufacturing of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry, and the development, manufacturing, and marketing of biotechnology-based products for the human pharmaceutical market. The firm focuses on Dextran and derivative products, including Iron Dextran and Dextran Sulphate and other specialty chemicals. The company was founded by Thomas C. Usher on June 14, 1979 and is headquartered in Toronto, Canada.

Q BioMed stock logo

Q BioMed OTCMKTS:QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

ReShape Lifesciences stock logo

ReShape Lifesciences OTCMKTS:RSLSD

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.

VG Life Sciences OTCMKTS:VGLS

$0.0001 0.00 (0.00%)
As of 06/13/2025 03:57 PM Eastern

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.